Elisabeth Glitzner-Zeis, PhD

Von vielversprechend bis praxisverändernd: Das sind die Highlights unserer Interviewpartner am ESMO 2019.

We will be reporting directly from the annual congress of the European Society for Medical Oncology (ESMO) in Munich, Germany, from October 19 to October 23.

As this year’s ASCO Annual Meeting draws near, we provide an outlook of the world’s largest oncology meeting in 2019. As always, we will report directly and on-site.

Results of a phase II clinical trial suggest that the PARP inhibitor rucaparib can stabilize and in some instances even improve disease of patients with somatic or germ line mutations of BRCA1, BRCA2 or PALB2.

Results from a phase II clinical trial presented at the AACR Annual Meeting 2019 demonstrate that the combination of nivolumab and ipilimumab could be efficacious in high-grade neuroendocrine carcinoma.

From Friday, March 29, to Tuesday, April 3, 2019, the 110th American Association for Cancer Research (AACR) Annual Meeting will take place in Atlanta (Georgia). medonline will be reporting directly from the congress.

"A congress after which we have to change our practice," was the conclusion of many experts interviewed by the medonline team during ESMO 2018. Here, we summarize their highlights from the congress.